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MICRONEEDLE PATCHES FOR HEPATITIS B VACCINATION  
YU AN LIN 
ABSTRACT 
  
 Hepatitis B is a liver disease caused by the hepatitis B virus infection. The 
likelihood of acute hepatitis B to progress to chronic hepatitis B, which significantly 
increases the risk of developing cirrhosis and hepatocellular carcinoma, is inversely 
related to the age of infection. At least 50% of the estimated 250 million individuals with 
chronic hepatitis B worldwide were infected through mother-to-child transmission or 
during early childhood, especially in areas where hepatitis B is highly endemic. Increased 
risk of perinatal transmission is associated with high levels of viremia in pregnant 
women. Thus, the hepatitis B birth dose, administered to infants within 24 hours of birth, 
is the main modality in the prevention of perinatal transmission and can prevent around 
90% of infants infected at birth from becoming chronic carriers.  
Although the hepatitis B vaccine has been commercially available for almost four 
decades, and has been proven to be effective and safe with correct storage and 
administration, hepatitis B remains a serious global health issue. Low and middle-income 
countries are disproportionately affected by hepatitis B with an estimated 45% of global 
population residing in an area of high hepatitis B prevalence where most infections are 
acquired perinatally. Furthermore, chronic hepatitis B infection accounts for around 45% 
of hepatocellular carcinoma cases, the sixth most common cancer worldwide and third 
most common cause of cancer-related death in Asia. The low hepatitis B immunization 
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coverage is due to the multiple barriers to effective vaccination in low and middle-
income countries. These barriers include the need for trained personnel to administer 
hypodermic injections, risk of sharps, vaccine refrigeration management, high cost of 
vaccine/vaccination, need for vaccine reconstitution, and vaccine wastage due to multi-
dose vials.  
To address several vaccination barriers and increase vaccination coverage, 
transdermal immunization with microneedle patches has been proposed as an alternative 
to conventional liquid vaccine formulations injected intramuscularly with hypodermic 
needles. There have been several studies and clinical trials on the use of microneedle 
patches for influenza vaccination that showed promising results. However, there is 
currently very limited information regarding the use of microneedle patches specifically 
for hepatitis B vaccination. Thus, this paper aims to explore the potential use of 
microneedle patches for hepatitis B vaccination by analyzing the effectiveness, usability, 
and acceptability of the vaccine. 
Recent studies have shown that microneedle patches with hepatitis B vaccine not 
only produced similar immunogenicity to that of a single injected hepatitis B vaccine but 
was also able to maintain antibody titers for a longer duration. Microneedle patch-based 
hepatitis B vaccine is also significantly more thermostable than conventional liquid 
formulations, which could drastically reduce vaccine cost and wastage. Finally, health 
care workers and vaccine administrators overwhelmingly preferred microneedle patches 
over hypodermic needles for vaccination. These results support the outstanding potential 
of microneedle-patch based hepatitis B vaccines to address several challenges with 
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existing vaccines and to increase vaccine coverage, especially in low and middle-income 
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 Hepatitis B (hepB) is a liver infection that is caused by the hepatitis B virus 
(HBV). HBV is transmitted through the exchange of bodily fluids and results in acute or 
chronic disease. Acute hepB infection is a short-term illness that can lead to fever, 
vomiting, dark urine, and jaundice. For some patients, hepB infection becomes chronic, 
meaning the HBV remains in the body for more than six months. Interestingly, the 
likelihood of disease progression from acute to chronic, which often results in liver 
cirrhosis and hepatocellular carcinoma, is inversely related to age at the time of infection. 
Around 90% of infants infected perinatally become chronic carriers, unless vaccinated at 
birth (Ott et al., 2012). Although the hepB vaccine has become commercially available 
for almost four decades, hepB remains a serious global health problem. HBV infection is 
still the major cause of liver cancer accounting for 42.3% (405,000/953,000) of total 
primary liver cancer globally in 2017 (C. Li & He, 2021). 
 This paper will first provide relevant background information on HBV and hepB, 
and then explore the thermostability of available hepB vaccines. Next, an introduction to 
microneedle patches (MNPs) for drug delivery will be provided, followed by an in-depth 





Hepatitis B Virus 
HBV is a prototype virus of the Hepadnaviridae (hepatotropic DNA virus) family 
which has a strong preference for infecting liver cells. Ten genotypes (A-J) have been 
identified with each genotype associated with a distinct geographic area (Liang, 2009). 
Baruch Blumberg et al. were the first to describe the association between the virus and 
hepatitis in 1967. In 1970, Dane et al. published electron micrographs of the HBV virions 
which are spherical particles about 40 to 42nm in diameter with a double-shelled 
structure (Fig.1) (Dane et al., 1970).  
 
Figure 1: Dane Particle. (Taken from Liang, 2009) 





The visualized infection virion (Dane particle) consists of a nucleocapsid made of 
hepatitis B core antigen (HBcAg) and viral genome (partially double-stranded circular 
DNA and 3.2kb in length) and polymerase in the core surrounded by a lipid envelope 
with hepatitis B surface antigen (HBsAg) (Liang, 2009).  
The replication cycle of HBV is summarized in Fig 2. The key step of the cycle is 
the DNA genome replication by RNA reverse transcription (Ganem & Prince, 2004). The 
initial phase of the HBV infection begins when mature HBV virions attach to cell-surface 
receptors. After membrane fusion, viral genome is transported to the nucleus. Exact viral 
disassembly mechanisms and intracellular transport of the genome at this step remain 
unclear but likely involve modification of the nucleocapsid core protein (Liang, 2009). 
Inside the nucleus, the viral genome is converted to a covalently close circular (ccc) form 
acting as the transcriptional template for host RNA polymerase II. The CCC form of 
HBV DNA is relatively resistant to immune clearance and antiviral action so considered 
the more stable part of the replication cycle (Liang, 2009). The continual presence of this 
HBV ccc DNA in the nucleus after infection is also a major barrier for hepB treatment 
and cure (Revill & Locarnini, 2016). Following transcription, all viral RNA is then 
transported to the cytoplasm, where translation takes place to produce the viral envelope, 
core, and polymerase proteins (Ganem & Prince, 2004). During this phase, the X and 
precore polypeptides are also produced. The X protein is necessary for replication of 
HBV in-vivo due to its role in host-cell signal transduction as well as host and viral gene 
expression (Ganem & Prince, 2004).  The HBV precore protein, or HBeAg, is involved in 
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down-regulating the host immune response (Walsh & Locarnini, 2012). After translation, 
nucleocapsids are assembled in the cytosol during which a single molecule of genomic 
RNA is incorporated into the assembling viral core. Reverse transcription begins when 
the viral RNA is encapsidated. The two viral DNA are synthesized sequentially. First, a 
DNA strand is made from the encapsidated RNA template. The RNA template is 
degraded while the DNA is being synthesized. The second DNA strand is then made 
from the newly synthesized first strand (Ganem & Prince, 2004). Some core particles 
with the mature genome are recycled back into the nucleus to be converted to ccc DNA 
for the maintenance of a stable intranuclear transcriptional template pool. The majority of 
the core particles bud into the endoplasmic reticulum where they acquire the viral 
envelopes containing the viral L (large), M (medium), and S (small) surface antigens 
(Ganem & Prince, 2004). The newly replicated HBVs are then exported out of the cell 




Figure 2: The Replication Cycle of HBV. (Taken from Ganem & Prince, 2004). 
HBV virions are internalized when bound to surface receptors. Viral core particles move to the 
hepatocyte nucleus where they form the ccc DNA that is used as the template for mRNA 
transcription. The mRNA undergoes translation in the cytoplasm to produce the viral surface, 
core, and X proteins. Viral capsids assemble incorporating the viral RNA (RNA packaging). Viral 
DNA is synthesized from reverse transcription. The core particles are either recycled as ccc DNA 
in the nucleus or bud into the endoplasmic reticulum to be enveloped and exported. The pink 




Immunopathogenesis of Hepatitis B Virus Infection 
 The HBV replication cycle is not directly cytotoxic to the hepatocytes. This fact 
supports the observation that many HBV carriers are asymptomatic and have minimal 
livery injury, despite extensive and ongoing intrahepatic replication of HBV (Ganem & 
Prince, 2004). In chimpanzees, for example, viral replication is almost completely 
abolished soon after CD3 and IFN- mRNA appear during early HBV infection, weeks 
before the peak of liver disease  (Thimme et al., 2003). The lack of histological or 
biochemical evidence of hepatocyte injury during the early phase of infection also 
suggests the possibility of noncytopathic control of HBV replication (Thimme et al., 
2003). Previous studies on the immunopathogenesis of HBV infection have established 
that the circulating virus particles are cleared by the humoral immune response to viral 
envelope antigens while the cellular immune response to the envelop, polymerase 
antigens, and nucleocapsid, clears infected cells (Francis V. Chisari & Ferrari, 1995). For 
acute hepB to progress into chronic hepB, HBV must persist by either not inducing a host 
immune response or by counteracting it. HBV can “hide” from the immune system by not 
inducing cytokines IFN-// in the first place (Wieland et al., 2004). In addition, it has 
been suggested by multiple studies that the primary determinant of disease pathogenesis 
and hepatocellular injury is the host immune response to HBV, particularly a weakened 
virus-specific T cell response (F. V. Chisari et al., 2010).  
T cells control several aspects of adaptive immunity throughout life, including 
responses to allergens, pathogens, and tumors (Kumar et al., 2018). They are critical for 
the body to maintain immune homeostasis and can do so for decades. T cells originate 
 
7 
from bone marrow progenitors and travel to the thymus for maturation and selection. In 
the thymus, progenitors from the bone marrow initially lack CD4+ or CD8+ coreceptor 
expression (CD4- /CD8-). Once they undergo T cell receptor rearrangement, they become 
double-positive thymocytes (CD4+ /CD8+) which are then selected to be (CD4+ /CD8-) or 
(CD4- /CD8+) single-positive thymocytes. Finally, they are exported to the periphery 
where they differentiate into naïve T cells, memory T cells, and regulatory T cells 
(Kumar et al., 2018). Naïve T cells can respond to new antigens, memory T cells help 
maintain long-term immunity from previous antigen activation, and regulatory T cells 
keep immune responses in check (Kumar et al., 2018). The main role of T cells evolves 
across a person’s lifespan which could influence the disease progression of hepB 
(visualized in Fig 3.) 
 
Figure 3: Changing Role of T Cells at Different Life Stages. (Taken from Kumar et al., 2018) 
T cell-mediated pathogen clearance and memory formation are important during the early years 
of life when humans are exposed to numerous antigens for the first time. After childhood, the 






Support for the role of T cell response in hepB pathogenesis includes the fact that 
the class I- and class II-restricted T cell responses to the virus are vigorous, polyclonal, 
and multispecific in acutely infected patients who successfully clear the virus while 
responses are relatively weak and more narrowly focused in chronically infected patients 
(Francis V. Chisari & Ferrari, 1995). Recent studies have further explored the association 
between chronic hepB and global T-cell dysfunction. More specifically, researchers have 
identified Bim-mediated apoptosis (Bim is an important apoptosis regulatory protein in 
the BCL-2 protein family) as a critical mechanism leading to the deletion of HBV-
specific CD8 T cells and the upregulation of this apoptotic mediator in chronic hepB 
patients (Maini & Schurich, 2010). Maini & Schurich further suggested that the HBV-
specific CD8 T cell apoptosis is a result of excessive coinhibitory signals from 
intrahepatic antigen presentation, including the Programmed Death-1 (PD-1) pathway. 
(PD-1 is an inhibitory receptor induced in activated T cells. PD-1 engagement by its 
ligands, PD-L1 and PD-L2, maintains peripheral tolerance preventing T cells from 
attacking other cells in the body (Patsoukis et al., 2020).) Expression of PD-1 ligands is 
upregulated on several intrahepatic cell types in inflammatory liver disease including 
chronic hepB (Kassel et al., 2009). Furthermore, defective antigen presentation has been 
shown to induce T cell tolerance through a combination of both PD-1 and CTLA-4 
(CTLA-4, or Cytotoxic T-lymphocyte antigen 4, on T cells with its ligand, B7, 
downregulates T cell response) (Maini & Schurich, 2010). Extrinsic regulation of T cells 
by suppressive mechanisms, such as the classical FoxP3+ regulatory T cell, have also 
been suggested to contribute to T cell tolerance in chronic hepB (Maini & Schurich, 
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2010). The forkhead box transcription factor, FoxP3, is a marker for regulatory T cell that 
is necessary and sufficient for their suppressive activity (Z. Li et al., 2015).  
 
Pathogenesis of Hepatitis B 
Acute Hepatitis B 
 Acute hepB can be either symptomatic or asymptomatic. Around two-thirds of 
acute HepB patients are asymptomatic (Liang, 2009). The elimination of HBV by 
noncytopathic mechanisms begins several weeks before the disease onset (Y.-F. Liaw & 
Chu, 2009). The other approximately one-third of infected adults develop clinical 
hepatitis symptoms, which can range from mild symptoms such as nausea or fatigue to 
more serious symptoms such as jaundice and possibly acute liver failure (Liang, 2009). 
According to the CDC, the incubation period for hepB is around 90 days after exposure 
to HBV and symptoms typically last for several weeks to up to 6 months, when it 
becomes chronic hepB. When cytolytic immune response with hepatocyte apoptosis and 
necrosis does occur in acute hepB, the preicteric phase, or the time before the appearance 
of jaundice, follows the incubation period and is marked by symptoms of body aches, 
fever, and nausea. During the preicteric phase, serum ALT (serum alanine 
aminotransferase is a viral marker) levels rise along with high levels of HBV DNA and 
HBsAg (Liang, 2009). This phase can last up to a week until the beginning of the icteric 
phase marked by the appearance of dark urine or jaundice. Viral levels begin to decrease 
during the icteric phase which lasts for around 2 weeks until jaundice resolves and 
HBsAg and HBV DNA are cleared from serum (Liang, 2009).  
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Chronic Hepatitis B 
As mentioned previously, the age of the patient when infected with HBV is 
inversely related to the likelihood of developing chronic hepB. The natural history of 
chronic hepB is also affected by the interaction of many other factors — HBV genotype, 
HBV viral mutations, HBV DNA level, host gender, host family history, other liver 
toxins (alcohol, non-alcoholic fatty liver disease), and possible coinfection (Croagh & 
Lubel, 2014). According to the European Viral Hepatitis Educational Initiative, there are 
four stages in the natural history (progression of disease in individual patients from the 
biologic onset to the outcome) of chronic hepB, namely, the immune tolerance, immune 
clearance, immune control, and immune escape (Fig 4) (Thomas, 2007). The four stages 
could be roughly divided by half according to the hepB e antigen status and the 
antibodies (HBeAb). HBeAg is an antigen produced from the region near the core gene 
and is used as a marker of active viral replication. The first half, phases 1 and 2, is 
HBeAg positive and HBeAb negative, which is reversed in the second half, phases 3 and 
4. This change from HBeAg positive and HBeAb negative to HBeAg negative and 
HBeAb positive is also known as seroconversion. It is important to note that not all 
chronic hepB patients spend the same amount of time in each phase and some may not go 
through all phases. In addition, distinct phases may not be recognized clinically due to the 





Figure 4: The Four Phases of Chronic Hepatitis B. (Taken from Croagh & Lubel, 2014) 
The figure outlines the four possible phases of perinatally acquired chronic hepB. Red solid line: 
HBV DNA with flares. Red dashed line: alternative course. Black dashed line: continuous ALT 
elevation. Black solid line: ALT flares.  
 
 
During the immune tolerance phase, there is active viral replication, evidenced by 
secretion of HBeAg and high levels of serum HBV DNA, but no symptoms and no 
significant increase in serum ALT (Wright, 2006). This first phase after acute HBV 
infection usually lasts between two to four weeks in healthy adults but often several 
decades in those infected perinatally. The immune clearance phase, or phase 2, is HBeAg 
positive chronic hepB, commonly presenting with high HBV DNA levels (but lower than 
phase 1) and intermittent or persistent ALT level elevations (Croagh & Lubel, 2014). 
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Immune-mediated liver damage occurs during this phase as well as the occurrence of 
spontaneous flares (generally defined as an elevation in ALT greater than 300IU/mL) that 
are usually clinically asymptomatic (Croagh & Lubel, 2014). The higher rates of cirrhosis 
in males could be accounted for by more common ALT flares in males than in females 
(A. S. Lok & Lai, 1990). Furthermore, the duration of the immune clearance phase 
strongly correlates with the risk of developing complications (Croagh & Lubel, 2014). In 
a study by Chen et al., patients with HBeAg seroconversion before age 30 have excellent 
prognosis, whereas those with delayed seroconversion after age 40 have significantly 
higher incidences of developing cirrhosis and hepatocellular carcinoma (Y.-C. Chen et 
al., 2010). The timing of HBeAg seroconversion is influenced by various factors, 
including age, environmental conditions, HBV genotype, and age at the time of infection. 
For example, 273 Chinese patients from a retrospective study (genotype B: 122 & 
genotype C: 147), showed that seroconversion was delayed for around 10 years in 
genotype C patients compared to genotype B patients (C.-J. Chu et al., 2002). Ideally, 
hepB patients expect a lifelong transition to the inactive carrier state after HBeAg to 
HBeAb seroconversion, however, seroreversion, the opposite of seroconversion may 
occur. In 512 Chinese patients (373 men, 139 women, aged 1-75 years), seroreversion 
occurred in 7.8% of patients who were HBeAg-negative at presentation and 32.3% of 
HBeAg-positive patients who cleared HBeAg (A. S. Lok et al., 1987). 
The immune control phase, or phase 3, is characterized by HBeAg loss, HBeAb 
growth, ALT normalization, and very low levels of HBV DNA which indicates chronic 
hepB clinical remission (Croagh & Lubel, 2014). Although the level of HBV DNA for 
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the immune control phase has been debated, recent guidelines have used the level of 2000 
IU/mL as a cut-off while acknowledging the possibility of HBV DNA up to 20000 
IU/mL (A. S. F. Lok & McMahon, 2009). Patients who show normal ALT levels and 2-3 
HBV DNA levels in the appropriate range (ideally less than 2000 IU/mL) for at least a 
year can be classified as in chronic hepB remission (Croagh & Lubel, 2014). 
In some patients, the immune control phase of chronic hepB is followed by phase 
4, the immune escape phase, characterized by a lack of serum HBeAg with detectable 
HBeAb, moderate to high levels of HBV DNA (greater than 2000 IU/mL), and more 
rapid progression of liver disease (Lazarevic et al., 2019). The detailed mechanism of this 
phase remains unclear, however, recent studies and case reports have identified high 
levels of S gene variability, including point mutations, from patients who experienced 
reactivation as a potential factor (Lazarevic et al., 2019). The S gene region of HBV is 
responsible for surface antigen expression and therefore point mutations could result in 









Long-term sequelae of chronic hepatitis B 
 The estimated 5-year survival rate is 97% for patients following the diagnosis of 
chronic hepB (Weissberg et al., 1984). However, one-third to one-fourth of people with 
chronic hepB are expected to develop progressive liver disease, including cirrhosis and 
hepatocellular carcinoma, which significantly increases morbidity and mortality (Pan & 
Zhang, 2005). Cirrhosis is scarring (fibrosis) of the liver caused by long-term liver 
damage and prevents the liver from working properly. For patients with compensated 
cirrhosis, the 5-year survival rate drops to 80 to 85% (C.-M. Chu & Liaw, 2006). The 
clinical and virologic features of HBV cirrhosis at initial clinical presentation vary 
considerably among patients, most likely due to the different ways that patients were 
identified (C.-M. Chu & Liaw, 2006). For example, in one study from Taiwan, the 
average age of the patients at presentation was 41 years since they were diagnosed with 
cirrhosis as part of follow-ups for chronic hepB (Y. F. Liaw et al., 1989). On the other 
hand, in another study from Taiwan with patients from referrals, the mean age of patients 
with cirrhosis at presentation was 45 years (Tsai et al., 1988). Furthermore, male gender 
is predominant in HBV cirrhosis globally, possibly due to the more frequent ALT flares 
mentioned in earlier paragraphs as well as more HBeAg seroreversion compared to 
females (C.-M. Chu & Liaw, 2006). The risk of rapid progression from chronic hepB to 
cirrhosis is increased with older age, presence of bridging hepatic necrosis (when 
necrosis involves more than one zone within a lobule and/or extends to adjacent lobules), 
and persistent active HBV replication (Fattovich et al., 1991).  
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 The main causes of death for patients with chronic hepB are liver failure and 
development of hepatocellular carcinoma. Hepatocellular carcinoma is a primary 
malignant neoplasm derived from hepatocytes, which accounts for about 80% of all liver 
cancers (R. X. Zhu et al., 2016). Table 2 summarizes several factors regarding the host 
and HBV that may increase the risk of hepatocellular carcinoma development (Pan & 
Zhang, 2005).  
 
Table 1. Risk Factors for Hepatocellular Carcinoma Development after HBV infection. 
(Adapted from Pan & Zhang, 2005) 
Types Risk Factors 
Host 
Male 
Older age (>45 years old) 
First degree relatives with hepatocellular carcinoma 
Viral and environmental 
Coinfection with HCV or HDV 
Alcohol intake 
Aflatoxin in diet 
Clinical 
HBeAg positive 
Detectable HBV DNA 
Cirrhosis 
Persistent HBV infection (HBsAg positive) 
 
Hepatocellular carcinoma is the sixth most common cancer worldwide and the third most 
common cause of cancer-related death in Asia (R. X. Zhu et al., 2016). Around 1% of all 
deaths in the world are attributed to hepatocellular carcinoma each year. Depending on 
the geographic regions, the incidence of hepatocellular carcinoma can be up to six times 
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higher in males compared to females and in those over 40 years old (R. X. Zhu et al., 
2016). Compared with non-carriers, there is a 100 fold increase in the risk of 
hepatocellular carcinoma development in chronically infected patients (Pan & Zhang, 
2005). Unlike other hepatitis, cirrhosis does not always precede the development of 
hepatocellular carcinoma in chronic hepB patients. For this reason, all HBV infected 
patients are recommended to get screening for hepatocellular carcinoma every 6 months 
regardless of the status of cirrhosis (Pan & Zhang, 2005). 
Chronic hepB infection remains a serious global health challenge affecting an 
estimated 250 million individuals and resulting in an estimated 887,000 deaths in 2015 
(Bohlke et al., 2003). Because HBV reverse transcription is error-prone, many HBV 
genotypes, mutants, and recombinants have emerged. To date, 10 HBV genotypes have 
been identified, located in different geographical regions as shown in Fig. 5 (Shi et al., 
2013; Sunbul, 2014). An understanding of the global distribution of different HBV 
genotypes and related viral factors has critical clinical importance because it helps to 
predict the clinical outcomes of chronic hepB which can vary greatly among patients. For 
example, both genotype A (prevalent in Northern Europe and sub-Saharan Africa) and D 
(prevalent in Africa, India, Europe, and Mediterranean countries) have a tendency for 
chronicity while genotype C (prevalent in southeast Asia) and D have frequent viral 
mutations. Furthermore, liver cirrhosis and disease progression to hepatocellular 
carcinoma are more commonly observed with genotypes C and D compared to other 
genotypes (Sunbul, 2014).  
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Genotype J is the newest HBV genotype defined which was identified in the 
Ryukyu Islands in Japan (Sunbul, 2014). 
 
Figure 5: Geographic Distribution of HBV Genotypes. (Taken from Shi et al., 2013) 
Size of the circle is not a representation of HepB prevalence. 
 
Geographic distribution of HBV genotypes could also provide epidemiological 
insight into the route of exposure. For example, in areas where perinatal (vertical) 
exposure is highly-endemic, genotypes B and C are more frequently documented while 






HEPATITIS B VACCINE 
 
Although there are several available clinical management options, there is 
currently no cure for hepB. Fortunately, the disease can be prevented by vaccines that are 
safe, available, and effective by providing up to 98-100% protection against HBV (C.-M. 
Chu & Liaw, 2006). The hepB vaccine is recommended for all infants at birth and can be 
administered as 2, 3, or 4 shots within 6 months. There are two types of hepB vaccines. 
The monovalent hepB vaccine contains highly purified HBsAg of the A2 genotype 
manufactured with recombinant DNA technology, which is the primary viral envelop 
protein responsible for immunogenicity and immunity from HBV infection (Jezek et al., 
2009). The combination hepB vaccine combines hepatitis B and hepatitis A antigens and 
is therefore effective against both viruses. The hepB vaccine is considered extremely 
safe. The estimated incidence of severe adverse events among vaccine recipients is 1.1 
per million vaccines (Bohlke et al., 2003). Current data suggest that the hepB vaccine is 
highly effective against all known HBV genotypes by providing cross-reactivity and 
cross-protection by A2 vaccines against non-A2 genotypes (Cassidy et al., 2011). The 
vaccines must be stored in a cold chain but should never be frozen. A cold chain refers to 
the requirement for vaccines to remain at refrigerator conditions from manufacturing to 
administration. 
One of the targets of the World Health Organization’s (WHO) Global Health 
Sector Strategy on Viral Hepatitis is to reach 90% coverage of hepB birth dose 
vaccination by 2030, yet almost 50% of WHO Member States do not or are unable to 
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provide the proper immunization at birth (Petit et al., 2017). Low and middle-income 
countries (LMICs) are disproportionately affected by HBV infection with a high 
prevalence in sub-Saharan regions of Africa and East Asia (Ott et al., 2012). An 
estimated 45% of the global population resides in an area of high HBV prevalence where 
most infections are acquired through perinatal transmission at birth (MacLachlan & 
Cowie, 2015). Most LMICs face significant vaccination barriers such as the need to 
maintain vaccine coldness against high ambient temperatures and unreliable electricity 
provision for cold chain maintenance (Karp et al., 2015). Table 3 includes a list of 
common barriers to effective vaccination in LMICs. 
 
Table 2. Effective Vaccination Barriers in LMICs. (Taken from Arya & Prausnitz, 2016)  
 Need for increased vaccine effectiveness  
 Need for trained healthcare providers  
 Need for effective supply chain  
 Risk of sharps  
 Vaccine wastage due to multi-dose vials  
 Need for vaccine reconstitution  
 Cost of vaccine/vaccination  
 
Vaccine cold chain challenges in LMICs 
 The push for universal childhood immunization in the 1980s by the WHO has 
been successfully implemented in many countries through various vaccination programs. 
Globally, smallpox was eradicated more than 30 years ago solely through the efforts of 
vaccination. Other infectious diseases such as yellow fever, poliomyelitis, rubella, and 
diphtheria have been eliminated in the U.S. as well as many other high and upper-middle-
income countries due to widespread national vaccination efforts. However, vaccine 
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storage and distribution challenges still limit vaccine coverage in some LMICs, thereby 
hindering the eradication of many infectious diseases. For example, the global incidence 
of polio has decreased by 99.9% since the Global Polio Eradication Initiative was 
launched in 1988. The remaining 0.1% of polio cases are primarily found in the three 
countries where polio is endemic — Afghanistan, Pakistan, and Nigeria. Global efforts 
are focused on strengthening vaccination services in these countries as the final push to 
eradicate polio by addressing challenges such as cold chain maintenance and researching 
thermostable polio vaccines. 
Vaccines are biological products with decreased activity over time. The loss of 
vaccine potency is accelerated when vaccines are not stored within their required 
temperature range. Almost all childhood vaccines, including polio and hepB vaccines, 
must be stored between 2C to 8C to ensure effective vaccine potency. Exposures to 
both heat and freezing temperatures are equally damaging to vaccine quality. Thus, a 
well-functioning cold chain is at the center of ensuring potent vaccines reach their 
intended population in an equitable and timely manner (Hanson et al., 2017).  
Unfortunately, a review of studies in 2007 reported that 75% - 100% of monitored 
vaccine shipments from 1985 to 2006 have been exposed to freezing temperatures 
(Matthias et al.). An updated literature review in 2017 concluded that 37.1% of analyzed 
vaccine shipments in LMICs were exposed to temperatures below recommended ranges 
(Hanson et al.). Although the number of damaged vaccines during transportation has 




Thermostability of the hepatitis B vaccine 
 The liquid hepatitis B vaccine contains purified recombinant HBsAg, phosphate 
buffer, and an aluminum hydroxide gel adjuvant (According to the CDC, adjuvants are 
ingredients used in some vaccines to help create stronger immune responses in vaccine 
recipients. Aluminum salts are common adjuvants that have been used safely in vaccines 
for more than 70 years) (Jezek et al., 2009). HepB vaccines can remain stable for up to 
four years if stored appropriately at 2C - 8C and is particularly sensitive to the cold. 
The vaccine freezes at -0.5C where virtually all of its immunogenicity is destroyed 
(Edstam et al., 2004). Vaccine quality is altered after freeze exposure primarily due to 
aggregation of the adjuvant-antigen particles and structural damage of the antigen (Fig. 6) 
(D. Chen et al., 2009). 
 
Figure 6: HBsAg & Aluminum Formulation Under Microscope. (Taken from Tonnis et al., 
2014) 
Left: HBsAg & aluminum formulation before free-thaw under microscope. Right: HBsAg & 
aluminum formulation after ten freeze-thaw cycles. Bar scale is 60 m. 
 
The requirement for a closely monitored vaccine cold chain poses a significant challenge 
for many LMICs due to limited infrastructure, trained personnel, and frequent power 
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outages leading to vaccine wastage. For example, Edstam et al. showed that only 70% of 
rural subjects in Mongolia developed protective antibody levels after HBV vaccination 
compared to 94% of urban subjects, and suggested that this discrepancy is due to 
damaged vaccines from freezing temperatures during provincial-to-rural transportation 
(2004). In addition to location, vaccine effectiveness related to thermostability is also 
affected by other factors such as the timing of administration. In a study based in rural 
Mongolia, the frequency of vaccine-induced immunity was significantly lower for those 
who received hepB vaccine at birth during winter, likely due to the increased risk of 
freeze exposure (Davaalkham et al., 2007). 
To date, there has been considerable efforts and funding dedicated to developing 
thermostable vaccines. For hepB vaccines, a thermostable formulation was introduced in 
2009 by Braun et al. The thermostable hepB vaccine contains all components of the 
original vaccine plus 7.5% (v/v) propylene glycol, 40 mM phosphate, and 40 mM 
histidine with a final pH of 5.2 (Braun, Jezek, et al., 2009). Propylene glycol at 5% is 
sufficient to protect the hepB vaccine from freeze damage at -10C, whereas as little as 
10% propylene glycol prevented measurable damage to temperatures as low as -80C 
(Braun, Tyagi, et al., 2009). The maximum potency of propylene glycol for intramuscular 
injection is 82.04% under FDA regulations. On the other hand, phosphate and histidine 
are used for heat damage protection. Phosphate anions in the hepB vaccine buffer react 
with the surface hydroxides from the adjuvant due to ligand exchange resulting in surface 
modification of the adjuvant to a certain degree (Jezek et al., 2009). The interaction 
between phosphate anion and hydroxide anion alters the pH microenvironment around 
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the adjuvant particle surface which subsequently affects the stability of the antigen 
adsorbed on aluminum adjuvant (Jezek et al., 2009). Thus, the stability of HBsAg can be 
controlled by adjusting the pH through changing the level of phosphate in the 
formulation. Jezek et al. found a direct relationship between the formulation’s phosphate 
concentration and the degree of surface modification. The optimal pH for HBsAg 
stability in an aqueous solution with phosphate is reported to be around 5.2. Moreover, 
without phosphate anions, HBsAg adsorbed onto aluminum hydroxide adjuvant is very 
unstable between the pH range of 5 and 9 (Jezek et al., 2009). The study results not only 
demonstrated that in-vitro antigenic reactivity of the adsorbed HBsAg was strongly 
dependent on the presence and concentration of phosphate but also that the current 
commercial hepB vaccine with a neutral pH is not ideal for antigen stability and should 
be more acidic (Jezek et al., 2009). 
 Compared to aqueous solutions, dry vaccines have improved storage and stability 
due to the reduced molecular mobility of the protein-based antigen (Saluja et al., 2010). 
However, the drying process can be harsh and damaging to the proteins. On the other 
hand, sugars can stabilize proteins, lipoplexes, liposomes, and various viruses during the 
drying process and subsequent storage (Amorij et al., 2008). If dried properly, the glass-
state amorphous sugar can incorporate the active substance in a matrix (Amorij et al., 
2008). This sugar matrix creates a physical barrier between particles (particle isolation) 
and reduces diffusion and molecular mobility (vitrification) which prevents aggregation 
and degradation of dried vaccines (Tonnis et al., 2014). Antigen can be damaged by sugar 
crystallization so it is crucial that sugar must remain in the glassy state during storage and 
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drying. Tonnis et al. increased the hepB vaccine thermostability and immunogenicity by 
using sugars, inulin or dextran and trehalose mixture, during the spray-freeze drying 
process. (Fig. 7) (2014).  
 
 
Figure 7: Figures of Powder Formulations Before Storage Under Scanning Electron 
Microscope. (Taken from Tonnis et al., 2014) 
(A) HBsAg-inulin. (B) HBsAg-dextran/trehalose and after 3 months of storage at 60C. (C) 
HBsAg-inulin. (D) HBsAg-dextra/trehalose. Bar scales for 1 m. 
 
 
Spray-freeze drying is a relatively novel technique that combines conventional spray 
drying and freeze-drying techniques. The three major steps of spray-freeze drying 
include: dispersion of bulk liquid solution into droplets, solidification of droplets by 
direct contact with the cold fluid (liquid nitrogen was used in the Tonnis et al. study), and 
sublimation of the solidified droplets at a very low temperature and pressure (Tonnis et 
al., 2014). Tonnis et al. chose the spray-freeze drying method since it produces spherical 
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particles that are smaller in size and therefore more suitable for pulmonary administration 
(2014). Moreover, the spray-freeze dried hepB vaccine was prepared without aluminum 
since the adjuvant is not suitable for pulmonary administration (Tonnis et al., 2014). The 
final thermostable products (prepared with inulin or a dextran and trehalose mixture) 
were able to retain the antigenicity and conformation of the HBsAg after 3 months of 
storage at 20C, which demonstrated significantly improved thermostability compared to 
the liquid formulations (Tonnis et al., 2014). 
 
Controlled temperature chain 
 Apart from researching thermostable hepB vaccine formulations, some efforts 
have shifted the focus to studying strategies to deploy hepB vaccines outside the cold 
chain to complement rather than replace the current formulations and systems. Although 
hepB vaccines should be stored and transported between 2C and 8C, WHO and some 
manufacturers are considering an off-label approach for storage >8C, known as 
controlled temperature chain (CTC), to increase vaccine coverage in LMICs (HBV 
Thermostability, 2016).  Consideration of the CTC strategy was mainly influenced by the 
critical 24-hour period of administrating the hepB vaccine birth dose to prevent perinatal 
transmission of the virus and the high risk of developing subsequent chronic infection. 
Unlike other vaccines, it is extremely difficult to schedule the hepB vaccine birth dose 
because of the uncertain timing of delivery, especially for home births (Petit et al., 2017). 
In addition to limited healthcare resources and access, barriers to the provision of birth 
dose in LMICs include cold chain challenges and the high prevalence of home births 
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(Petit et al., 2017). Rates of home birth are as high as 83% in the poorest regions in 
Southeast Asia and 52% in Central Africa (Montagu et al., 2017). WHO’s consideration 
for CTC is also influenced by in-vitro studies from current manufacturers who found that 
vaccine potency results, despite an average decrease by 16%, met minimum lot release 
specifications following storage at 37C for a month (Petit et al., 2017). Despite the 
decrease in hepB vaccine potency due to heat exposure, WHO recommends the CTC 
approach especially in resource-poor countries with limited healthcare access and a 
substantial number of home births without immediate infant immunization.  
 After WHO recommended the CTC strategies in some LMICs, Scott et al. used a 
mathematical model of perinatal HBV transmission and disease progression to calculate 
and compare per 1000 births the total HBV-related disability-adjusted life-years and costs 
with and without the CTC strategy (2018). The CTC strategy was cost-saving in regions 
of sub-Saharan Africa, Latin America and Caribbean, East Asia and Pacific, and North 
Africa and Middle East (Scott et al., 2018). Perhaps more importantly, the CTC strategy 
resulted in more cost savings in areas with above-average HBV prevalence and below-
average birth immunization within an individual country, which aligns with the goal of 
WHO to improve immunization equity (Scott et al., 2018).  
In a survey conducted by WHO, 25 responses from countries in Western Pacific 
and African Regions were used to gauge interest in the CTC strategy for hepB vaccines. 
“Vaccines not reaching newborns at home” and “vaccines are not available in all health 
facilities due to cold chain constraints” were the two main challenges limiting the hepB 
vaccine birth dose coverage (Petit et al., 2017). Moreover, 7 countries from the Western 
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Pacific Regions and 11 from African Regions, or 72% of the responding countries, 
confirmed the need for hepB vaccines manufactured for CTC use to improve the 
provision of birth doses (Petit et al., 2017). 
 MenAfriVac for Meningitis A was the first vaccine prequalified and licensed 
for CTC purpose in 2012 which can be stored at up to 40C for up to 4 days. 155,000 
people were vaccinated using the CTC approach from the first field use of MenAfriVac 
in Benin, a country in West Africa (Zipursky et al., 2014). From the campaign 
experience, 98.7% of supervisors and 100% of vaccinators would prefer to continue the 
use of CTC in the future due to reduced logistic burden and more people vaccinated 
(Zipursky et al., 2014). The CTC approach eliminated the need for ice packs which 
significantly reduced the weight of vaccine carriers, allowed vaccinators to stay in the 
field for longer, and reduced the need to return to health facilities in the evenings to store 
unused vaccines (Petit et al., 2017).  
 
Cost of vaccine wastage in LMICs 
Since 2000, the Global Alliance for Vaccines and Immunization (GAVI) Alliance 
Partners have made significant progress to meet the goals of the Global Immunization 
Vision and Strategy developed by WHO. From 2000 through 2019, GAVI helped 
vaccinate more than 822 million children which generated more than $150 billion 
through economic benefits by preventing illness, death, and long-term disability. Yet, 
almost 20% of the birth cohort in GAVI countries still are not immunized with basic 
vaccines (GAVI, 2021). Furthermore, the vaccine delivery cost in GAVI countries was 
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around $2.2 billion in 2012 and is projected to increase every year due to introduction of 
new and more expensive vaccines and a continued increase in birth cohort size (GAVI, 
2021).  
Karp et al. generated a model for the total end-to-end systems costs associated 
with delivering routine immunization based on previous work from WHO, PATH, and 
the Decade of Vaccines. The model estimated that vaccine thermostability could affect up 
to 18% of the main drivers of cost including wastage (According to the WHO, vaccine 
wastage is defined as the sum of vaccines discarded, lost, damaged, or destroyed), 
outreach, cold chain equipment, and storage. Thus, a fully thermostable portfolio of 
routine immunization vaccines may save $125-150 million from total system costs every 
year across GAVI countries (Karp et al., 2015). 
Vaccine wastage from multi-dose vials can be of significant cost. Several 
vaccines are licensed as multi-dose vials (e.g., ten-dose). In general, there is a positive 
correlation between the number of vaccine doses per vial and vaccine wastage rate (Arya 
& Prausnitz, 2016). It is estimated that waste rates for ten-dose vials could be up to 40% 
and 25% for lyophilized and liquid vaccines, respectively (Arya & Prausnitz, 2016). 
Despite the widespread optimism, abundant research, and existing technology for 
manufacturing thermostable vaccines, no hepB vaccines are currently licensed for CTC 
use and there are extremely few commercialized thermostable vaccines. Furthermore, 
many lyophilized (freeze-dried) vaccine powder in one vial must be reconstituted (mixed) 
with the diluent (liquid) in another before administration. This may present several 
challenges to effective vaccination including healthcare workers’ education on proper 
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vaccine reconstitution knowledge and techniques. The liquid diluent for many vaccines 
must be stored in a refrigerator which could be difficult to manage in LMICs with 
unreliable electricity supply. Moreover, “sterile water” is used as the liquid diluent for 
several vaccines leading to additional barriers to successful vaccine reconstitution and 
administration in LMICs with limited resources. 
Recent research and development of microneedle patches (MNPs) for drug 





Microneedle Patches Background Information 
 Several drugs are not designed for oral administration due to concerns with poor 
drug absorption from enzymatic degradation by the gastrointestinal tract or liver. In that 
case, injections with a painful hypodermic needle are the most common alternative. 
However, the need for expert administration, risk of sharps, and patient hesitancy are 
major factors limiting the use of injections. Transdermal drug delivery with a patch is 
therefore a different approach considered for its possibility of controlled release over time 
and likely higher levels of patient acceptance (Arya & Prausnitz, 2016). One of the first 
and biggest barriers to successful transdermal drug delivery at a therapeutic rate is to 
cross the skin’s outer stratum corneum layer (Prausnitz, 2004). Only drugs with very 
specific physicochemical properties (low melting point, adequate lipophilicity, and 
molecular weight <500 Da) can pass the stratum corneum successfully (Donnelly et al., 
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2010). Therefore, various methods to increase skin permeability have been researched in 
the past, including chemical enhancers and ultrasound pressure waves, all to disrupt and 
create “holes” in the stratum corneum structure for drug molecules to pass through 
(Prausnitz, 2004). These methods create gaps with nanometer diameters to allow the 
transport of small molecules but not enough to create clinically significant damage to the 
skin. 
 An alternative approach to transport larger particles across the skin is to use 
microscopic needles to create larger transport pathways of micron dimensions (Prausnitz, 
2004). When applied to the skin, microneedles will puncture the skin, bypassing the 
stratum corneum, and create transient aqueous transport pathways to increase transdermal 
permeability (Donnelly et al., 2010). The micron-scale holes created by microscopic 
needles are smaller than those made by hypodermic needles (usually between 0.0035-
inch to 0.106-inch in diameter) or minor skin abrasions in daily life and therefore 
presumably safe. Furthermore, since the primary barrier to transport is located in the 
upper 10-15 m of skin and nerves are found only in deeper tissue, microneedles should 
potentially cause no pain and allow access to the systemic circulation  (Donnelly et al., 
2010). 
 The first experimental demonstration of microneedles was in the 1990s when 
microfabrication tools needed to manufacture them became available by the 
microelectronics industry. Since the first demonstration of microfabricated microneedles 
for transdermal drug delivery in 1998 by Henry et al., interest in the field of microneedles 
has grown rapidly, especially in the use of microneedles patches (MNPs) for 
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pharmaceutical applications. There is already a sizable and rapidly growing market for 
MNP products in the cosmetic industry indicating that MNPs are efficacious, safe, and 
widely accepted (Prausnitz, 2017). Thus, many researchers and manufacturers are 
optimistic about the use of MNPs for pharmaceutical purposes. 
 
Microneedle Patches Fabrication and Manufacturing 
Design objective 
The main design objectives of microneedle fabrication include: (a) drug delivered 
across skin’s stratum corneum and correct dose delivered for effective drug delivery; (b) 
targeted delivery to skin for faster onset of systemic delivery of drugs and improved 
immunogenicity of vaccines; (c) reduced expertise needed for patch application and no 
need for reconstitution for increased access to drug; (d) improved stability for less 
reliance on cold chain storage and transportation; (e) reduced or eliminated sharps waste 
and single-use, single-dose, fully disposable for increased safety and reduced wastage; (f) 
lack of pain and reduced patch wear time for improved patient compliance; and (g) 
reduced package size and low-cost manufacturing for cost savings (Prausnitz, 2017). 
 
Microneedle patches design 
  The first microneedle device was fabricated from silicon, but many other 
materials have been used in subsequent studies including glass, ceramic, stainless steel, 
galactose, dextrin, maltose, and other polymers (Donnelly et al., 2010). Various 
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microneedle manufacturing methods have also been explored in the past few years, such 
as laser drilling, chemical isotropic etching, injection molding, and lithography-
electroforming-replication (Donnelly et al., 2010). There are also different microneedle 
shapes and sizes investigated. Generally, microneedles can be divided into two types 
based on the structures: in-plane and out-of-plane microneedles. For out-of-plane 
microneedles, the length of microneedles is perpendicular to the substrate while the 
length of microneedles is parallel to the substrate (Fig. 8) (He et al., 2019).  
 
Figure 8: (A) Out-of-plane and (B) In-plane Microneedles. (Taken from He et al., 2019) 
  A typical microneedle is between 150-1500 microns long, 50-250 
microns wide, and has 1-25 microns tip thickness (Waghule et al., 2019).  Microneedle 
arrays usually contain hundreds to thousands of microneedles, placed linearly, on a patch 
usually the size of a thumbnail with skin adhesive. There are 4 major categories of 
microneedle fabrication, visualized in Fig. 9: 1) solid microneedles for increased skin 
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permeability during pretreatment, “poke and patch” (2) microneedles coated with drugs 
that can dissolve in the skin, “coat and poke” (3) polymer microneedles that encapsulate 
drug and fully dissolve in the skin, “poke and release” and (4) hollow microneedles for 
drug delivery into the skin, “poke and flow” (Kim et al., 2012).  
 
Figure 9: Transcutaneous Drug Delivery Methods with Microneedles. (Taken from Kim et 
al., 2012) (A) illustrates the application of the 4 different types of microneedle patches. (B) 
illustrates the drug delivery after application of microneedle patches.  
  
 The “poke and patch” approach uses MNPs without drugs to puncture the skin for 
pretreatment followed by a drug-loaded patch (or other topical formulation) placed over 
the residual microneedle pores. For the “coat and poke” approach, the microneedle 
surface is coated with drugs in a water-soluble matrix that dissolves off the microneedles 
into the skin when in contact. The “poke and release” approach uses microneedles that 
are water-soluble and encapsulate drugs so the microneedles dissolve in the skin and 
release their encapsulated content when the patch is inserted. Finally, the “poke and 
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flow” approach uses microneedles encapsulated with drug to enable a slow release. 
Different from “poke and release”, the microneedles with “poke and flow” do not 
dissolve in the skin and are often made of hydrogels that swell upon insertion for the 
drugs to diffuse out of the microneedles and into the skin (Prausnitz, 2017). There are 
pros and cons to each approach. For example, the “coat and poke” and the “poke and 
release” approaches only require patients to apply the MNPs for a few minutes before 
they are discarded. The “poke and release” approach also avoids generating sharps waste. 
The “poke and patch” approach can deliver larger doses because drug is contained in a 
patch backing that delivers the drug continuously, yet this approach requires a two-step 
process (Prausnitz, 2017). The “poke and flow” approach can also deliver larger doses for 
the same reason but requires patients to wear the MNPs properly for an extended period 
of time (Prausnitz, 2017). Thus, different approaches should be considered when 
designing and manufacturing MNPs. 
 
Microneedle patches design parameters 
 MNP performance can be strongly influenced by the geometry of individual 
microneedles and the overall patch. As mentioned previously, the stratum corneum layer 
of the skin represents the major barrier for transdermal drug delivery. It is around 15 m 
thick when dry and about 48 m thick when fully hydrated (Yan et al., 2010). A 
microneedle should thus be designed to be just long enough to penetrate the stratum 
corneum layer but not hit the dermis layer where nerves could cause pain sensation. A 
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study evaluating various microneedle lengths (from 100 to 1100 m) and densities (from 
400 to 11,900 needles/cm2) reported that microneedle arrays with lower needle densities 
(<2000 needles/ cm2) were more effective in enhancing drug flux if the microneedles 
were long enough (>600 m) (Yan et al., 2010). This may be due to the “bed-of-nails” 
effect, where the insertion force is distributed among too many microneedles and 
therefore not enough to penetrate the skin (Prausnitz, 2017). There was no significant 
drug flux increase with the use of microneedles with lengths longer than 600 m. 
 Davis et al. explored two critical mechanical events associated with MNPs: the 
force required to insert microneedles into living skin and the force microneedles can 
withstand before fracturing using different microneedle geometries (Davis et al., 2004). 
Their experimental results showed that the insertion force depended significantly on the 
outer radius of the needle tip but not wall thickness, therefore, suggesting a linear 
dependence of insertion force on interfacial area (Davis et al., 2004). In contrast, fracture 
forces were dependent on wall thickness but fracture forces were almost always greater 
than insertion forces (Davis et al., 2004). 
  
 Microneedle Structures and Molds 
 The microfabrication technology for MNPs relies heavily on the techniques used 
to produce microelectronic chips in the field of microelectronic engineering. Silicon is 
traditionally used in the integrated circuit industry and also the most commonly used 
material for fabricating microneedles for the “poke and patch” and “coat and poke” 
methods. Other commonly seen materials include metals or non-dissolving polymers, yet 
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silicon is still preferred for its biocompatibility and its ability to penetrate skin without 
breakage in the skin (Y. Li et al., 2019). The “poke and release” and “poke and flow” 
approaches, on the other hand, often use molds made from masters with microneedle 
structures. 
 The reactive ion etching process is one of the most commonly used techniques to 
fabricate silicon microneedles. Etching refers to the process of removing materials from 
the surface, basically chipping away a solid to create various structures. The process can 
be categorized into dry or wet etching depending on whether liquid chemicals were used. 
Lithography, particularly photolithography, is usually the first step. The method exposes 
UV light to polymers through a patterned mask. Briefly, UV light is irradiated onto a 
plastic coverslip manufactured in the pattern of microneedle array and placed above the 
microneedle backing layer. (Kochhar et al., 2013). The plastic film contains transparent 
circles that allow the UV light to pass through to form microneedles after washing. A 
diagram of the procedure is included below to help with visualization (Fig. 10). The 
substrate surface is typically a silicon wafer but could also be other materials such as gold 




Figure 10: Photolithography for Microneedle Fabrication. (Taken from Kochhar et al., 2013) 
TMSPMA: 3-(trimethoxysilyl) propyl methacrylate (TMSPMA). SiO2: silicon dioxide. PEGDA: 
Polyethylene (glycol) Diacrylate. 
 
The fabrication of the “coat and poke” MNP is used here as an example to 
understand the important steps in microfabrication using molds, illustrated in Fig. 11. 
First, a stainless-steel mold is used to create a PDMS (polydimethylsiloxane) mold. Next, 
the drug is added to the PDMS mold using a vacuum to help the drug distribution in the 
mold. After drying, a PEGDA (polyethylene (glycol) diacrylate) prepolymer is placed on 
the mold with a vacuum to help with filling. PEGDA is a polymer often used for 
microneedle fabrication for its biocompatibility and approval from the Food and Drug 
Administration (Gao et al., 2019).  Finally, UV light is irradiated to better fix the drugs 
onto the microneedles before the drug-coated MNP is peeled off from the mold (Gao et 




Figure 11: Coated Microneedle Patch Microfabrication. (Taken from Gao et al., 2019)  
 
Microneedle Patches for Vaccination 
  The skin is the largest immune organ in our body and has a key role in our 
immune system with densely populated antigen-presenting cells. Thus, MNPs can be 
used for targeted vaccination (He et al., 2019). A diagram summarizing the skin immune 
system is illustrated in Fig. 12. MNPs for vaccine delivery has several advantages 
compared to the most commonly used hypodermic needle injections. First, hypodermic 
needle injections require trained personnel for the correct technique and proper sharp 
disposal. Whereas MNPs can be easily applied by the patients with a method similar to 
that of a Band-Aid. In addition, vaccines administered through dissolving MNs eliminate 
the risk of sharps-related injuries and exposure to bloodborne pathogens. Unsafe injection 
practices are responsible for an estimated 1.7 million HBV infections and 315,000 
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hepatitis C infections annually (WHO | Injection Safety Policy and Campaign, n.d.).  
Second, pain and needle phobias are experienced by many patients which could affect 
patient compliance (Kim et al., 2012). Third, microneedles could be manufactured to 
contain vaccine formulations that do not require refrigeration thereby reducing the cost of 
storage and vaccine wastage. Forth, vaccine doses are usually less than 0.1mg which is 
ideal for MNPs design (Yan et al., 2010). Fifth, MNPs contain dried vaccines that can 
dissolve into the skin rapidly after application thus removing the need for reconstitution 
(Arya & Prausnitz, 2016). Finally, the use of MNPs can reduce the overall cost of 
vaccination by reducing the need for trained personnel, simplifying the supply chain, 
limiting vaccine wastage, minimizing the risk of sharps, and eliminating the need for 
vaccine reconstitution (Arya & Prausnitz, 2016). 
 
Figure 12: Summarized Immune System in the Skin. (Ita, 2016) 
LC: Langerhans cell. SC: stratum corneum. Ag: antigen. dDC: dermal dendritic cells. 
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 On the other hand, there are some drawbacks and concerns with the use of MNPs 
for vaccination, mainly due to the limited research associated with the new technology. 
First, different strategies are needed to overcome the stratum corneum barrier for 
effective drug delivery. Second, the adjuvant commonly used in liquid vaccine 
formulations often caused adverse reactions when administered directly onto the skin. 
Third, the use of microneedles could limit drug loading. Forth, there is a large degree of 
uncertainty associated with MNP manufacturing cost and scalability. Finally, there is 
currently very limited clinical data as well as industry interest regarding MNPs for 
vaccination purposes. 
Previous studies  
 Since the first introduction of MNPs for transdermal drug delivery in 1998, there 
has been a rapid growth in the number of studies focusing on the use of MNPs for 
vaccination. There has also been a shift from the use of non-dissolvable microneedles to 
dissolvable microneedles to eliminate risks of sharps and waste. The majority of early 
studies have mostly looked into the use of MNPs for influenza vaccines. One such study 
by Sullivan et al. investigated the use of novel dissolving MNPs with biocompatible 
polymer microneedles containing inactivated influenza virus vaccine. The microneedles 
completely dissolve in the skin minutes after application (Sullivan et al., 2010). The MNP 
showed promising results with strong cellular and humoral immune responses after one 
administration and conferred protective immunity against lethal viral challenge in mice 
(Sullivan et al., 2010). Advantages of using MNPs over conventional hypodermic needles 
also include improved IgA lung titers, more antibody-secreting cells, and a more efficient 
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viral clearance (Sullivan et al., 2010). The robust immune response elicited from the 
transdermal vaccine are likely from dendritic cells in the epidermis and the proximal 
draining lymph nodes (Sullivan et al., 2010). This could explain the stronger immune 
response from the MNP compared to intramuscular injection since the innate immune 
system plays a critical role in the adaptive immune response (Sullivan et al., 2010). 
 In 2017, Arya et al. examined the usability, tolerability, and acceptability of 
MNPs with placebo in 15 human subjects (Arya et al., 2017). MNPs were reported to be 
painless, did not cause swelling, and reported mild erythema were fully resolved by day 7 
(Arya et al., 2017). The differences of delivery efficiency between investigator-
administrated and subject self-administrated drug was not statistically significant 
suggesting that MNPs can be self-administrated with no or minimal training. 98%-99% 
of microneedles in a given patch successfully punctured the skin’s surface for both 
groups. (Arya et al., 2017). Lastly, all subjects reported a much higher preference for 
using MNPs over conventional hypodermic needles (Arya et al., 2017). 
 The first clinical trial (phase 1) of dissolvable MNPs for influenza vaccination 
was conducted in 2015 at Emory University (Fig. 13) (Ng et al., 2017). 100 participants 
between the ages of 18 to 49 who were not immunocompromised, not pregnant, did not 
have significant dermatological disorders, and naïve to the 2014-2015 influenza vaccine 
were enrolled in the study and randomly equally assigned among four groups: (1)MNP, 
(2) placebo MNP, (3) intramuscular injection, (4) subject self-administered MNP (Ng et 
al., 2017). No serious adverse events were reported from the study. Tenderness and pain 
were reported by 60% and 44% of the participants respectively in the intramuscular 
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injection group (Ng et al., 2017). In the MNP group, 66% of participants reported 
tenderness and no participants reported pain (Ng et al., 2017). There was no significant 
titer difference between the MNP group, the intramuscular injection group, and the 
subject self-administered MNP group (Ng et al., 2017). Furthermore, seroconversion 
percentages after 28 days were similar between the intramuscular injection group and the 
MNP group (Ng et al., 2017). 
 
Figure 13: Dissolvable Microneedle Patch Against Influenza. (Taken from Ng et al., 2017)  
(a) 100 microneedle array on MNP (b) MNP was administered on subject wrist (c) influenza 










Microneedle Patches for Hepatitis B Vaccine 
 
Antigenicity kinetics study 
 Poirier et al. have previously demonstrated that dissolvable HBsAg MNP made of 
hydroxyethyl starch and chondroitin sulfate is thermostable and antigenic after 6-month 
storage at 50C (Poirier et al., 2017). Zhu et al. then explored the kinetics of HBsAg 
stability during the microneedle fabrication process using different sugars as stabilizers 
(trehalose, chitosan, sucrose, and glucose). The microneedle fabrication process involved 
drying of drug formulations, polymer gel casting, and demolding (D. D. Zhu et al., 2019). 
Mold casting and drying processes during the microneedle fabrication decreased the 
bioactivity of the original pure HBsAg vaccine to 96.7%, possibly due to the repeated 
changes between liquid and solid states (D. D. Zhu et al., 2019). Thus, different sugars 
were added to stabilize the bioactivity of HBsAg vaccine. Trehalose, in particular, was 
able to maintain 98.9% of HBsAg antigenicity after the same fabrication process with 
molding and drying explained earlier (D. D. Zhu et al., 2019). The use of trehalose as a 
stabilizer in MNPs also produced almost twice as much IgG titer compared to that of 
MNPs without added stabilizer and maintained around 90% and 80% of initial 
antigenicity after a week-long and 3-month long storage at 60C, respectively. (D. D. Zhu 
et al., 2019). 
 Scanning electron microscope was used to study the changes in physical 
characteristics of HBsAg with various sugar stabilizers before and after a week-long 
storage at 60C (Fig. 14).  Before storage, plain HBsAg (Fig. 14A) showed an irregularly 
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distributed pattern, HBsAg with sucrose (Fig. 14B) showed a densely packed pattern, and 
HBsAg with trehalose (Fig. 14C) showed a stratified pattern (D. D. Zhu et al., 2019). 
After storage, plain HBsAg (Fig. 14A1) showed isolated granules, indicating that HBsAg 
could experience conformational changes from exposure to high temperature resulting in 
decreased antigenicity; HBsAg with sucrose (Fig. 14B1) became even more tightly 
packed after exposure to high temperature; and HBsAg with trehalose (Fig. 14C1) 
formed molecules with locally wavy microlayers which could better protect HBsAg 
antigenicity, although the exact mechanism remains unclear (D. D. Zhu et al., 2019). 
 
Figure 14: Scanning Electron Microscope Images Before and After Storage. (Taken from D. 
D. Zhu et al., 2019)  
(A): plain HBsAg, (A1): plain HBsAg after storage, (B): HBsAg with sucrose, (B1): HBsAg with 






 Although there are no clinical trials of MNPs for hepB vaccination yet, various 
animal studies have been reported along with different modifications to enhance drug 
delivery. 
Transdermal immunization in Mice  
 In 2012, Hirschberg et al. combined the use of vesicle formulations and MNPs for 
hepB vaccination. The use of antigen associated vesicles with deformable bilayers can 
better transport the drug across the stratum corneum layer and have been shown to 
produce antibody titers by transdermal injection that is significantly higher than by 
conventional intramuscular injection (Hirschberg et al., 2012). Two types of vesicles 
were prepared in the study by Hirschberg et al.: the first vesicle (L595 vesicle) contained 
surfactant L595 (sucrose laurate ester) for bi-layer formation and PEG-8-L 
(octaoxyethylene laurate ester) for micelle formation, the second vesicle (sPC vesicle) 
contained SPAN 80 as a detergent and soybean phosphatidylcholine. Moreover, cholera 
toxin was added as the adjuvant (Hirschberg et al., 2012). Empty vesicles of the two 
types were used as control along with vesicles associated with HBsAg. These designed 
vesicles were applied onto intact mice skin or with the “poke and patch” approach. 
(Hirschberg et al., 2012). 
 Experimental results supported the critical role of skin pretreatment by MNPs to 
create detectable antibody responses. Furthermore, the combination that produced the 
best immunization effect was the sPC-HBsAg vesicles containing cholera toxin as the 
adjuvant which produced similar seroconversion results to that of intramuscular 
vaccination (Hirschberg et al., 2012). Although the mechanism of cholera toxin as an 
 
46 
adjuvant remains unclear, it is suggested that Langerhans cells in the epidermis can be 
activated by cholera to become potent antigen presenting cells. Thus, administration of 
sPC-HBsAg vesicles containing cholera toxin onto MNP-pretreated skin provides a 
promising alternative to conventional hepB vaccination. 
 Another study by Guo et al, used a combination of newly developed Functional 
MicroArray (FMA) and hydrogel patch for hepB vaccination using the “poke and patch” 
method (Guo et al., 2013). FMA is essentially a MNP that contains 484 solid, octagonal 
pyramidal-shaped, silicon microneedles while the hydrogel patch included HBsAg and 
cholera toxin as the adjuvant (Guo et al., 2013) 
 Experimental results confirmed the use of pre-treatment skin with FMA MNPs 
produced significantly higher HBsAg-specific IgG antibodies than without pre-treatment 
similar to the findings from Hirschberg et al. mentioned previously (Guo et al., 2013). 
Furthermore, hydrogel was able to retain significantly more HBsAg antigen activity after 
3-week storage at 4C, 37C, and 45 C than liquid formulations across every observed 
temperature (Guo et al., 2013). Finally, the study also found transdermal immunization 
with FMA MNPs and hydrogel could maintain IgG titers for a longer duration than with 




Figure 15: The Duration of Protective Antibody Levels. (Taken from Guo et al., 2013)  
MN: microneedle. CTB: cholera B toxin. IM: intramuscular injection. H: HBsAg. 
 
 
Transdermal immunization in Rhesus macaques  
 In addition to mice, rhesus macaques were studied for hepB vaccination using 
dissolvable MNPs by Cuevas et al. Aluminum is commonly found in the liquid hepB 
vaccine formulations as an adjuvant as described previously in this paper. However, 
when used in transdermal immunization, aluminum frequently caused skin irritation after 
contact and formed nodules in both human and animal subjects (Sirinavin et al., 1991). 
An aluminum adjuvant-free hepB vaccine was thus chosen in the study by Cuevas et al. 
The dissolvable MNP was fabricated with a mold using similar methods described in the 
microneedle fabrication section which produced a 10 by 10 microneedle array with 24 g 
of HBsAg at the needle portion available to be administered (Cuevas et al., 2018). One 
dose of dissolvable MNPs was subsequently applied on a shaved area on the back of 
rhesus macaques along with standard hepB vaccine injection in the control group. The 
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MNPs were pressed onto the skin for 30 seconds by thumb and left on for 20 minutes to 
simulate the intended method of MNP administration according to the Ng et al. clinical 
trial (2017) described in earlier paragraphs (Cuevas et al., 2018). Blood samples from 
vaccinated rhesus macaques were collected weekly for HBsAg antibody titers. At week 
seven, at least 50% of each group had reached HBsAg antibody titers greater than 10 
mIU/mL (considered seroprotective in humans) (Cuevas et al., 2018). However, the 
adjuvant-free MNP group had a lower absolute titer level than the control group with 
intramuscular injection adjuvanted vaccine (Cuevas et al., 2018).  
 Similar studies of cellular and humoral immune responses to dissolvable MNPs 
for hepB vaccination is also reported by Choi et al. in 2019.  An adjuvant-free hepB 
vaccine in dissolvable MNP was compared with intramuscular injections of hepB vaccine 
both with and without aluminum adjuvant in rhesus macaques (Choi et al., 2019). The 
MNP was applied with the same method as described in the MNP studies by Ng et al. and 
Cuevas et al. HBsAg antibody titers were measured weekly after vaccination and a 
second booster vaccine was administered 8 weeks after the first dose (Choi et al., 2019). 
 Although the HBsAg antibody titers produced from MNPs were lower than those 
from intramuscular injections (with and without aluminum adjuvants), the MNP-induced 
antibody titers still reached levels greater than 10 mIU/mL (considered seroprotective in 
human) (Choi et al., 2019). These results were similar to and supported the data observed 
in the Cuevas et al. study (2018). Choi et al. also examined the cellular immune responses 
by analyzing HBsAg-specific IL-2-, IL-4- (T-helper 2 [TH2]-type cytokine), and IFN-- 
(T-helper 1 [Th1]-type cytokine) producing T cells using an enzyme-linked immunospot 
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assay (2019). Adjuvant-free dissolvable MNPs were able to produce Th1 and Th2 levels 
that were higher than those produced by the intramuscular adjuvant-free method and 
demonstrated a positive correlation between cytokine levels and HBsAg antibody levels 
(Choi et al., 2019). Furthermore, dissolvable MNP hepB vaccine was also able to induce 
high levels of inflammatory cytokines (TNF-, TGF-, IL-6, and IL-1) and chemokines 
(MIP-1, MIP-1, and MCP-1) (Choi et al., 2019). These cytokines and chemokines are 
important as part of the immune response. For example, IL-1 and TNF- are involved 
in Langerhans cells migration and the subsequent dendritic cell accumulation in lymph 
nodes (Choi et al., 2019).  
Transdermal immunization in rabbit 
 Na et al. studied the histological changes and immune response to a polylactic 
acid-based MNP coated with HBsAg using a “coat and poke” approach in rabbits (2020). 
Mechanical tests demonstrated that microneedles made with polylactic acid can 
successfully penetrate the stratum corneum layer in the skin (Na et al., 2020). HBsAg in 
liquid formulations retained 0% antigenicity after 2-month storage at 40C whereas 
HBsAg in solid formulations retained 97% antigenicity under the same storage 
conditions, thereby supporting the improved storage ability of  MNPs (Na et al., 2020). 
Furthermore, 74% of HBsAg was released after the MNP was applied onto skin for 30 
minutes, suggesting that the MNP could produce similar immunogenicity to that of a 
single injected hepB vaccine (Na et al., 2020) Lastly, HBsAg MNPs used in in-vivo 







Hepatitis B (hepB) is caused by the hepatitis B virus (HBV) primarily infecting liver 
cells. The likelihood of acute hepB to progress to chronic hepB, which increases the risk 
of developing cirrhosis and hepatocellular carcinoma by around 100-fold compared to 
non-carriers, is inversely related to the age of infection. Thus, the hepB birth dose, 
administered to infants within 24 hours of birth, is especially important to prevent 
perinatal transmission, especially in low and middle-income countries (LMICs) where 
hepB is highly endemic.  
 There is currently no cure for hepB, fortunately, the hepB vaccine has been 
commercially available for almost four decades, and has been proven to be safe and 
effective by providing up to 98-100% protection against HBV with correct storage and 
administration. Yet, chronic hepB remains a serious global health issue affecting around 
250 million individuals globally. LMICs are disproportionately impacted by hepB with 
an estimated 45% of the global population residing in an area of high hepB prevalence. 
Furthermore, HBV infection is still the major cause of hepatocellular carcinoma, the sixth 
most common cancer worldwide and third most common cause of cancer-related death in 
Asia. The low hepB immunization coverage in LMICs can be attributed to multiple 
immunization barriers, including the need for trained healthcare providers to administer 
hypodermic injections, risk of sharps, vaccine refrigeration management, high cost of 
vaccine/vaccination, the need for vaccine reconstitution, and vaccine wastage from multi-
dose vials. Lyophilized thermostable vaccines and the controlled temperature chain 
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strategy are two of the many proposed methods to address these immunization barriers. 
However, they present with their own set of challenges. For these reasons, microneedle 
patches (MNPs) for vaccination has been proposed as an alternative for conventional 
intramuscular injections. 
 The micron-scale wounds created by the MNPs are smaller than those made by 
hypodermic needles or minor skin abrasions in daily life. Administration of MNPs has 
also been reported by multiple studies to be painless, likely improving patient 
compliance. There are four major categories of microneedle fabrication, namely “poke 
and patch”, “coat and poke” poke and release”, and “poke and flow”. Moreover, the skin 
is an ideal target for immunization since it is our largest immune organ and has a key role 
in our immune system with densely populated antigen-presenting cells. In summary, 
immunization with MNPs have several advantages compared to conventional hypodermic 
needle injections — 1) MNPs can be easily applied with a method similar to that of a 
Band-Aid and thus reduces the need for trained personnel, 2) MNPs, especially dissolve 
microneedles, eliminate the risk of sharps-related injuries and exposure to bloodborne 
pathogens, 3) painless administration of MNPs could improve patient compliance, 4) 
MNPs could be manufactured to contain vaccine formulations that do not require 
refrigeration thereby reducing the cost of storage and vaccine wastage, 5) MNPs can be 
administered without the need for reconstitution.  
 In-vitro studies of MNPs for influenza vaccination have demonstrated that MNPs 
were able to elicit a stronger immune response than intramuscular injection likely from 
the important interaction between our innate and adaptive immune response. Various 
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studies have also demonstrated the thermostability of MNPs for hepB vaccination, such 
as the use of trehalose as a stabilizer. Since the common adjuvant used in liquid hepB 
vaccine formulations, aluminum, frequently caused skin irritation, cholera toxin, or 
adjuvant-free MNP formulations have been researched and showed promising 
immunogenicity results. 
 With increased immunization coverage, the hepB vaccine has incredible potential 
to dramatically decrease hepatitis B-associated morbidity and mortality, especially in 
LMICs. More research is needed to support this potential, including additional clinical 
trials, thermostability studies in the field, unexpected risks or unintended consequences 
associated with microneedles, and detailed reports of manufacturing cost. With these 
considerations in mind, this paper concludes that microneedle patches provide a powerful 
and promising novel technology as an alternative to conventional liquid hepatitis B 
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